Nonagen Bioscience
Nonagen Bioscience is a biotechnology company dedicated to discovering and developing breakthrough diagnostics for human diseases, with a focus on oncology. Their mission is to reduce the burden of cancer globally through innovative diagnostics, and their vision is to drive and shape biomedical research. They aim to provide doctors with advanced diagnostic tools for disease detection, therapy choice, and disease monitoring, particularly for bladder cancer with their flagship product, Oncuria.
Industries
Nr. of Employees
small (1-50)
Nonagen Bioscience
Los Angeles, California, United States, North America
Patents
Products
Oncuria (urine-based multiplex protein immunoassay)
A multiplex urine immunoassay that quantifies a defined panel of ten protein biomarkers and applies a multivariate classifier to generate a risk score for bladder cancer detection, monitoring, and prediction of therapy response.
Nexus-Dx (neoadjuvant chemotherapy response predictor)
A diagnostic under development designed to predict response to neoadjuvant chemotherapy in bladder cancer patients using biomarker-based analysis.
FibraChek (noninvasive liver fibrosis test)
A noninvasive diagnostic test in development for assessing liver fibrosis in at-risk populations, based on licensed metabolomics discovery technology.
Oncuria®
A breakthrough multiplex immunoassay for the quantitative detection of biomarkers in urine associated with bladder cancer, offering high sensitivity and specificity across tumor grades and stages.
Oncuria TM
A multiplex urinalysis test measuring 10 cancer-associated biomarkers in urine to predict response to intravesical BCG treatment in non-muscle-invasive bladder cancer patients.
Nexus-Dx™
A neoadjuvant chemotherapy response predictor test for bladder cancer.
Oncuria (urine-based multiplex protein immunoassay)
A multiplex urine immunoassay that quantifies a defined panel of ten protein biomarkers and applies a multivariate classifier to generate a risk score for bladder cancer detection, monitoring, and prediction of therapy response.
Nexus-Dx (neoadjuvant chemotherapy response predictor)
A diagnostic under development designed to predict response to neoadjuvant chemotherapy in bladder cancer patients using biomarker-based analysis.
FibraChek (noninvasive liver fibrosis test)
A noninvasive diagnostic test in development for assessing liver fibrosis in at-risk populations, based on licensed metabolomics discovery technology.
Oncuria®
A breakthrough multiplex immunoassay for the quantitative detection of biomarkers in urine associated with bladder cancer, offering high sensitivity and specificity across tumor grades and stages.
Oncuria TM
A multiplex urinalysis test measuring 10 cancer-associated biomarkers in urine to predict response to intravesical BCG treatment in non-muscle-invasive bladder cancer patients.
Nexus-Dx™
A neoadjuvant chemotherapy response predictor test for bladder cancer.
Services
Availability of a multiplex urine-based biomarker test as an LDT through partnership with a CLIA-certified, GMP-compliant laboratory for clinical sample testing and reporting.
Collaborative manufacturing or licensing arrangements with reagent and multiplex assay manufacturers to produce and distribute multiplex immunoassay panels.
Availability of a multiplex urine-based biomarker test as an LDT through partnership with a CLIA-certified, GMP-compliant laboratory for clinical sample testing and reporting.
Collaborative manufacturing or licensing arrangements with reagent and multiplex assay manufacturers to produce and distribute multiplex immunoassay panels.
Expertise Areas
- Diagnostic assay development
- Biomarker discovery and proteomics
- Analytical validation and assay qualification
- Clinical study design and clinical validation
Key Technologies
- Multiplex bead-based immunoassay
- Multianalyte assay with algorithmic analysis (MAAA)
- Protein biomarker panels
- Urine-based liquid biopsy
News & Updates
Nonagen Bioscience and HMI have agreed to an exclusive licensing agreement for HMI’s liver fibrosis/cancer detection technology, aiming to bring a noninvasive liver fibrosis detection test to the US market.
Nonagen Bioscience announced strategic milestones including clinical trial completions, FDA submissions, and pipeline expansion, positioning for growth and commercialization.
CMS has decided on the payment rate for Nonagen's Oncuria suite of bladder cancer tests, effective January 1, 2024, marking a significant milestone in bladder cancer care.
Dr. Charles Rosser discussed the development and current status of Oncuria, highlighting its potential to revolutionize bladder cancer diagnostics.
Partnership to develop and bring to market a noninvasive liver fibrosis detection test.
Timothy Johnson appointed as Executive Chair, bringing extensive industry experience to guide the company's growth.
Nonagen Bioscience and HMI have agreed to an exclusive licensing agreement for HMI’s liver fibrosis/cancer detection technology, aiming to bring a noninvasive liver fibrosis detection test to the US market.
Nonagen Bioscience announced strategic milestones including clinical trial completions, FDA submissions, and pipeline expansion, positioning for growth and commercialization.
CMS has decided on the payment rate for Nonagen's Oncuria suite of bladder cancer tests, effective January 1, 2024, marking a significant milestone in bladder cancer care.
Dr. Charles Rosser discussed the development and current status of Oncuria, highlighting its potential to revolutionize bladder cancer diagnostics.
Partnership to develop and bring to market a noninvasive liver fibrosis detection test.
Timothy Johnson appointed as Executive Chair, bringing extensive industry experience to guide the company's growth.